OGN News and Press, Organon & Co. From 02/16/22

Acquisition Immediately Adds to Organon’s Suite of Contraceptive Offerings and Continues to Build on Strong Foundation in Women’s Health Around the World Organon (NYSE: OGN) today announced that it has acquired the rights from Bayer AG to Marvelon ® an...

Last year proved to be a record-breaking year for IPOs, amid government stimulus and soaring valuations. However, this year, the market is under pressure because of the looming interest rate hikes. Though the market could remain under pressure in the upcoming months, Wall Street analysts expe...

Organon Canada Declares Paid Time Off for All Employees on International Women's Day; All Employees in Canada to Focus on Their Own Health in Recognition of Growing Women's Health Inequity Canada NewsWire As the COVID-19 pandemic continues to have a disproportionate ...

As the COVID-19 pandemic continues to have a disproportionate impact on women , Organon issues a call to action for other leaders to create opportunities to focus on women’s health Organon (NYSE: OGN), a global women’s health company, is designating Int...

Organon (NYSE: OGN), will release its fourth quarter and full year 2021 financial results on February 17, 2022, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EST. Interested parties may access the live call via webcast on the Organon website at ...

NEXPLANON® (ETONOGESTREL EXTENDED-RELEASE SUBDERMAL IMPLANT) NOW COVERED BY ONTARIO, BRITISH COLUMBIA AND NOVA SCOTIA'S PUBLIC FORMULARIES Canada NewsWire KIRKLAND, QC , Jan. 11, 2022 /CNW/ - Organon Canada — Organon (NYSE: OGN) — is pleased to...

Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for a citrate-free, high-concentration (100 mg/mL) formulation of SB5 (adalimumab-bw...

Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the 40th Annual J.P. Morgan Healthcare Virtual Conference on Monday, January 10, 2022 at 2:15 p.m. ET. Investo...

Expands women’s health pipeline with novel candidates targeting endometriosis and polycystic ovarian syndrome (PCOS) Organon (NYSE: OGN), a global women’s healthcare company, today announced the completion of its acquisition of Forendo Pharma, a clinical-stage ...

Organon has seen material share price weakness as of late. The selling appears to be unjustified, however, considering Organon's recent business fundamentals. Meanwhile, OGN pays a respectable dividend with a low payout ratio, and has growth catalysts in its Women's Health and Bio...